HC Wainwright Raises Earnings Estimates for Alpha Cognition

Alpha Cognition Inc. (NASDAQ:ACOGFree Report) – Equities researchers at HC Wainwright raised their Q3 2025 earnings per share estimates for shares of Alpha Cognition in a research note issued on Monday, October 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.39) per share for the quarter, up from their previous forecast of ($0.45). HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. HC Wainwright also issued estimates for Alpha Cognition’s Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.45) EPS, Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.94) EPS.

Alpha Cognition (NASDAQ:ACOGGet Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.19). The business had revenue of $1.66 million during the quarter, compared to the consensus estimate of $2.32 million.

Separately, Wall Street Zen downgraded shares of Alpha Cognition from a “hold” rating to a “sell” rating in a research note on Saturday, October 18th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $18.00.

Get Our Latest Stock Report on ACOG

Alpha Cognition Price Performance

NASDAQ ACOG opened at $6.90 on Wednesday. The stock has a market capitalization of $144.21 million, a PE ratio of -4.31 and a beta of 2.63. Alpha Cognition has a 1 year low of $3.75 and a 1 year high of $11.54. The business’s 50-day moving average is $7.97 and its 200 day moving average is $8.15.

Insider Buying and Selling

In other Alpha Cognition news, Director Phillip Joseph Mertz sold 27,778 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $9.00, for a total value of $250,002.00. Following the transaction, the director directly owned 22,462 shares of the company’s stock, valued at $202,158. This represents a 55.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Robert James Wills acquired 15,000 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was purchased at an average cost of $8.49 per share, for a total transaction of $127,350.00. Following the completion of the acquisition, the director owned 15,000 shares in the company, valued at approximately $127,350. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 14.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC acquired a new stake in shares of Alpha Cognition during the 2nd quarter worth $112,000. Massar Capital Management LP acquired a new stake in shares of Alpha Cognition during the 2nd quarter worth $116,000. Villere ST Denis J & Co. LLC grew its holdings in shares of Alpha Cognition by 201.0% during the 1st quarter. Villere ST Denis J & Co. LLC now owns 71,778 shares of the company’s stock worth $363,000 after purchasing an additional 47,928 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Alpha Cognition during the 2nd quarter worth $600,000. Finally, Manatuck Hill Partners LLC grew its holdings in shares of Alpha Cognition by 74.6% during the 2nd quarter. Manatuck Hill Partners LLC now owns 117,000 shares of the company’s stock worth $1,092,000 after purchasing an additional 50,000 shares in the last quarter.

Alpha Cognition Company Profile

(Get Free Report)

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

See Also

Earnings History and Estimates for Alpha Cognition (NASDAQ:ACOG)

Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.